Ultra sensitive MRD testing in Blood for Multiple Myeloma patients
M-inSight® is now available
MRD monitoring in blood is now possible!
Sebia offers powerful tools for the Myeloma Patient's Journey
Sebia's poster at ADLM Chicago 2024 received 2 awards!
M-INSIGHT®
M-inSight® provides deeper insights into Multiple Myeloma monitoring
High sensitivity, at MRD level
Because deeper response require more sensitive testing, M-inSight® has been developed to detect very low level of M-protein. M-inSight® sensitivity in blood is equivalent to MRD evaluation in bone marrow and 1,000 x more sensitive than IFE. The Clonotypic peptides targeting avoids the interference with the polyclonal background and with therapeutic monoclonal antibodies.
Treatment performance monitoring
M-inSight® tracks low level disease over time, monitors kinetics and depth of response and detects early progression of the disease. Thanks to its non-invasive sampling, clinicians can ask for M-inSight® as frequently as needed for a dynamic monitoring of MRD.
Personalized
The monoclonal Ig clone signature is unique and harbors multiple mass spectrometry-suitable clonotypic peptides for each patient with Multiple Myeloma. M-inSight® is able to detect clonotypic peptides coming from different clones.
Non invasive
M-inSight® can monitor MRD with a simple blood draw. This is a major improvement compared to bone marrow – MRD testing that present critical limitations: require invasive and painful bone marrow aspirate, provide limited timepoints and introduce the risk of false negative results due to tumor heterogeneity.
M-inSight®
On the forefront of technological advancements
1,000x
more sensitive than IFE*
95%
of patients MRD positive by NGS in BM was detected by M-inSight® in blood
100%
of MM patients can be monitored in blood
Our recent publications
View all publications
Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry - Blood Cancer J. 2023
Somayya Noori, Charissa Wijnands, Pieter Langerhorst, Vincent Bonifay, Christoph Stingl, Cyrille Touzeau, Jill Corre, Aurore Perrot, Philippe Moreau, Hélène Caillon, Theo M Luider, Thomas Dejoie, Joannes F M Jacobs , Martijn M van Duijn
Blood Cancer J. 2023 Feb 24;13(1):30. doi: 10.1038/s41408-023-00803-z. PMID: 36828828; PMCID: PMC9957984.
Resources
Get helpful information about MRD and M-inSight®
PRODUCT INQUIRY
M-inSight® has been validated for clinical use
M-inSight® is a Laboratory Developed Test (LDT) being offered by Corgenix Clinical Laboratory, a CLIA certified, CAP accredited, high complexity clinical laboratory.
